Clin2
NCT07533942Likely a fitRecruiting

Testing JZP3507 for Recurrent Grade 2 or 3 Brain Tumors

Meningioma

Part of Brain & nervous system, Cancer clinical trials.

This study tests a new drug called JZP3507 for people with meningioma (a type of brain tumor, grades 2 or 3) that has come back or grown despite previous treatment. The goal is to see if this medication can slow or shrink the tumor.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
30 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older
  • Your meningioma (brain tumor) is confirmed by biopsy and is grade 2 or 3
  • Your tumor has grown or progressed, and standard treatments have failed, aren't suitable, or you chose not to have them
  • You can swallow pills by mouth and are generally well enough to do daily activities (Karnofsky score of at least 70)
  • Your blood work and organ function meet certain safe levels (checked within 2 weeks of starting)
  • You can provide old imaging scans (from at least 9 months ago) and tumor tissue samples for the study

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07428616Recruiting· Phase 2
Study of Zanzalintinib for recurring meningioma

This trial tests a drug called Zanzalintinib for people with meningioma that has come back or grown despite past treatments. It aims to see if the drug can stop or slow tumor growth.

Birmingham, Alabama
NCT05425004Recruiting· Phase 2
Cabozantinib for recurrent or worsening meningioma tumors

This Phase 2 trial studies cabozantinib, a targeted pill medicine, for meningioma that has come back or is getting worse after standard treatment like surgery or radiation. It aims to shrink tumors and slow progression when other options may have limited benefit.

Miami, Florida
NCT06804655Not yet recruiting· Phase 2
Personalized drug testing for stubborn brain tumors

This study tests a new way to choose treatment for people with brain tumors that have not responded to standard therapies. Your tumor sample is analyzed in the lab to find which drugs might work best for you, and then you receive a personalized treatment plan.

Basel, Basel-Landschaft
NCT05254197Recruiting
Brain tumor monitoring study with follow-up brain scans

This study follows people with lower-grade (WHO grade 2 or less) brain tumors using repeat MRI scans over time. It helps doctors understand how these tumors change and which patients may safely delay treatment at first.

Seoul
NCT06650163Recruiting· Phase 1
New imaging test for brain tumor surgery planning

This trial tests a new kind of PET scan that uses a special tracer (Zr-89 crefmirlimab berdoxam) to help doctors see brain tumors more clearly before surgery. If you are scheduled to have your brain tumor removed, this scan may give your surgeon extra information to guide the operation.

Los Angeles, California
NCT07501559Recruiting· Phase 1/Phase 2
Study of JL15003 for recurrent glioblastoma

This trial is testing a new drug (JL15003) given directly into the brain tumor using a small device called an Ommaya reservoir. It is for people whose glioblastoma has come back despite standard treatments. You will need to have had a polio vaccine booster before starting.

Shanghai

Hear when a new Meningioma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.